Sankyo Pharma GmbH

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Subsidiary

Employees: -

Market Cap: -

Website

Clinical Trials

Olmesartan Medoxomil and Diabetic Nephropathy

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus
Diabetic Nephropathy
Proteinuria
Renal Disease

First Posted Date: 2006-08-15

Last Posted Date: 2006-10-09

Lead Sponsor: Sankyo Pharma Gmbh

Target Recruit Count: 300

Registration Number: NCT00362960

Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension

Phase 4

Completed

Conditions: Essential Hypertension

Interventions: Drug: olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary

First Posted Date: 2006-04-05

Last Posted Date: 2010-12-10

Lead Sponsor: Sankyo Pharma Gmbh

Target Recruit Count: 694

Registration Number: NCT00311155

Locations: 🇮🇹
Ospedale San Paolo, Milano, Italy
🇵🇹
Hospital Fernando da Fonseca, Amadora Amadora, Portugal
🇧🇪
Centre Hospitalier du Bois de l'Abbaye et de Hesba, Department of Intensive Care, Seraing, Belgium

and more 37 locations

Amlodipine as add-on to Olmesartan in Hypertension

Phase 3

Completed

Conditions: Essential Hypertension

First Posted Date: 2005-09-22

Last Posted Date: 2018-12-24

Lead Sponsor: Sankyo Pharma Gmbh

Target Recruit Count: 429

Registration Number: NCT00220220

Olmesartan as an add-on to Amlodipine in Hypertension

Phase 3

Completed

Conditions: Essential Hypertension

First Posted Date: 2005-09-22

Last Posted Date: 2018-12-24

Lead Sponsor: Sankyo Pharma Gmbh

Target Recruit Count: 632

Registration Number: NCT00220233

Efficacy and Safety of Pactimibe in Patients With Atherosclerosis

Phase 2

Completed

Conditions: Atherosclerosis

First Posted Date: 2005-09-16

Last Posted Date: 2007-03-28

Lead Sponsor: Sankyo Pharma Gmbh

Target Recruit Count: 200

Registration Number: NCT00185146

Olmesartan in Essential Hypertension

Phase 3

Completed

Conditions: Essential Hypertension

Interventions: Drug: olmesartan medoxomil
Other: placebo
Drug: olmesartan medoxomil oral tablets, hydrochlorothiazide oral tablets

First Posted Date: 2005-09-16

Last Posted Date: 2008-04-29

Lead Sponsor: Sankyo Pharma Gmbh

Target Recruit Count: 2333

Registration Number: NCT00185172

Locations: 🇨🇭
PFC Pharma Focus Consultants AG, Zurich, Volketswil, Switzerland
🇵🇹
EUROTRIALS Lda, Lisboa, Portugal
🇳🇱
IMRO TRAMARKO International bv, Berghem, Netherlands

and more 5 locations

Olmesartan Medoxomil in Diabetes Mellitus

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2
Cardiovascular Disease
Kidney Disease

Interventions: Drug: Placebo Tablets
Drug: Olmesartan medoxomil

First Posted Date: 2005-09-16

Last Posted Date: 2010-01-20

Lead Sponsor: Sankyo Pharma Gmbh

Target Recruit Count: 4449

Registration Number: NCT00185159

Olmesartan Medoxomil in Atherosclerosis

Phase 3

Completed

Conditions: Essential Hypertension
Atherosclerotic Cardiovascular Disease

Interventions: Drug: olmesartan medoxomil
Drug: atenolol
Drug: Hydrochlorothiazide

First Posted Date: 2005-09-16

Last Posted Date: 2007-12-14

Lead Sponsor: Sankyo Pharma Gmbh

Target Recruit Count: 165

Registration Number: NCT00185185

Olmesartan Medoxomil in Hypertension and Renal Impairment

Phase 3

Completed

Conditions: Essential Hypertension
Renal Impairment

Interventions: Drug: Olmesartan medoxomil
Drug: Losartan
Drug: Furosemide oral tablets

First Posted Date: 2005-09-09

Last Posted Date: 2010-10-14

Lead Sponsor: Sankyo Pharma Gmbh

Target Recruit Count: 393

Registration Number: NCT00151827

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy